退伍军人人群中从瑞舒伐他汀到阿托伐他汀的治疗药物互换
Therapeutic Interchange From Rosuvastatin to Atorvastatin in a Veteran Population.
作者信息
Dowd Caitlin M, Tillmann Jacob J
机构信息
was a PGY-2 ambulatory care pharmacy resident at the time this article was written, and is a clinical pharmacist and pharmacy residency program director at the North Florida/South Georgia Veterans Health System. Dr Dowd is now an ambulatory care clinical pharmacy specialist at Johns Hopkins Hospital in Baltimore, Maryland.
出版信息
Fed Pract. 2015 Dec;32(12):20-24.
Abstract
A change in formulary statins was not associated with any differences in liver enzymes or lipid control for patients but did result in significant cost savings at the North Florida/South Georgia Veterans Health System.
摘要
对于患者而言，调整处方他汀类药物与肝酶或血脂控制方面的任何差异均无关联，但在北佛罗里达/南佐治亚退伍军人医疗系统确实实现了显著的成本节约。
相似文献
1
Therapeutic Interchange From Rosuvastatin to Atorvastatin in a Veteran Population.
Fed Pract. 2015 Dec;32(12):20-24.
2
Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Ann Pharmacother. 2020 May;54(5):405-413. doi: 10.1177/1060028019888487. Epub 2019 Nov 12.
3
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4.
4
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Clin Ther. 2008 Jul;30(7):1345-57. doi: 10.1016/s0149-2918(08)80061-6.
6
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Curr Med Res Opin. 2007 Dec;23(12):3055-68. doi: 10.1185/030079907x242809.
7
Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
J Prim Care Community Health. 2014 Jul;5(3):180-7. doi: 10.1177/2150131914520991. Epub 2014 Feb 11.
8
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins.
Curr Med Res Opin. 2008 Sep;24(9):2477-87. doi: 10.1185/03007990802321709. Epub 2008 Jul 24.
9
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002.
10
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia.
Value Health Reg Issues. 2014 Dec;5:48-57. doi: 10.1016/j.vhri.2014.07.007. Epub 2014 Nov 13.
本文引用的文献
1
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12.
2
Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization.
J Manag Care Pharm. 2005 Oct;11(8):681-6. doi: 10.18553/jmcp.2005.11.8.681.
3
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation. 2004 Jul 13;110(2):227-39. doi: 10.1161/01.CIR.0000133317.49796.0E.
4
Current overview of statin-induced myopathy.
Am J Med. 2004 Mar 15;116(6):408-16. doi: 10.1016/j.amjmed.2003.10.033.
5
Pharmacologic characteristics of statins.
Clin Cardiol. 2003 Apr;26(4 Suppl 3):III32-8. doi: 10.1002/clc.4960261507.
6
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
Am J Health Syst Pharm. 2002 Mar 15;59(6):529-33. doi: 10.1093/ajhp/59.6.529.
7
Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program.
Pharmacotherapy. 2001 Sep;21(9):1130-9. doi: 10.1592/phco.21.13.1130.34616.
8
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Pharmacotherapy. 2001 Apr;21(4):410-5. doi: 10.1592/phco.21.5.410.34491.
Zotero 插件